Loading organizations...

§ Private Profile · Sunnyvale, CA, USA
Smartlens is a technology company.
Smartlens develops solutions for glaucoma and other anterior eye diseases. Its core offering is an electronics-free contact lens for remote intraocular pressure monitoring. This platform integrates a smart drug delivery system and an AI-powered imaging solution. The company leverages microfluidic technology in ultra-thin devices, providing real-time, data-driven treatment insights.
Murat Baday, Savas Komban, and Sevda Agaoglu founded Smartlens in 2015, stemming from Stanford University research. They identified an unmet need for continuous, personalized treatment in chronic eye conditions. Their insight transformed traditional ophthalmic care into a proactive, data-driven system, applying advanced solutions to long-standing challenges.
Smartlens products serve ophthalmologists and a global patient base, enabling personalized, proactive disease management. It aims to advance eye care beyond conventional methods, offering solutions for chronic conditions with limited prior innovation. Its vision is to ensure eye diseases no longer compromise quality of life, leading to superior health outcomes globally.
Smartlens has raised $16.2M across 3 funding rounds.
Smartlens has raised $16.2M in total across 3 funding rounds.
Smartlens is a clinical‑stage ophthalmic technology company developing a data‑driven platform for continuous intraocular pressure (IOP) monitoring and AI‑enabled anterior‑segment exams, anchored by its flagship miLens contact‑lens sensor and the Slit IQ imaging/AI system[2][1]. Smartlens positions its products to shift glaucoma and anterior‑segment care from episodic office measurements to continuous, remote monitoring and standardized tele‑exams, and is currently advancing pivotal US clinical trials and FDA clearance activities for miLens[2][4].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick final note: Smartlens is best understood as a clinical‑stage medtech company combining novel microfluidic contact‑lens sensing and AI imaging to address a clear clinical gap in glaucoma and anterior‑segment care, with pivotal regulatory and commercial milestones imminent[1][2][4].
Smartlens has raised $16.2M across 3 funding rounds. Most recently, it raised $5.2M Other Equity in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 14, 2025 | $5.2M Venture Round | SAM Goldberger | Boutique Venture Partners, Graphene Ventures, Harvard Business School Alumni Angels OF NEW York | Announced |
| Oct 1, 2025 | $5M Series U | — | Ambit Health Ventures, Blackwood Healthcare Breakthroughs, Connecticut Innovations | Announced |
| Jul 1, 2023 | $6M Series A | Ambit Health Ventures | Blackwood Healthcare Breakthroughs, Connecticut Innovations, 3E Bioventures Capital, Boutique Venture Partners, Graphene Ventures, Plaisance Capital Management, Sophia Innovation Capital, Stanford University, WS Investments | Announced |
Smartlens has raised $16.2M in total across 3 funding rounds.
Smartlens's investors include Sam Goldberger, Boutique Venture Partners, Graphene Ventures, Harvard Business School Alumni Angels of New York, Ambit Health Ventures, Blackwood Healthcare Breakthroughs, Connecticut Innovations, 3E Bioventures Capital, Plaisance Capital Management, Sophia Innovation Capital, Stanford University, WS Investments.